Huge thanks to all of our co-authors, including Sr. Author Dr. Peter Siegel @McGillGCI, Veronique Ouellet @CRCHUM, Jakob Lafon @McGillMed, Matt Annis, @rima_ezz & @Afnan_AAT ! @McGill_MDPhD @oncopole @OncoAlert

This finding highlights the subtype-specific prognostic significance of CIRBP in breast cancer and suggests differential underlying mRNA targets bound and modulated by CIRBP in TNBC and HR + tumors, respectively. More on this to come in amazing fundamental work by @rima_ezz !

In TNBC, high levels of CIRBP expression by IHC was associated with poor prognosis in uni+multivariate analysis. However, in HR + primary BC, CIRBP expression was correlated with favorable prognosis (the opposite)!

We accessed the amazing patient tissue resources from @CancerseinQC and stained 1406 hormone receptor positive (HR +) and 281 triple negative primary breast cancers (TNBC) with immunohistochemistry for CIRBP

In mice, when we knocked down CIRBP in MDA-MB-231 triple-negative breast cancer cells, we saw no difference in primary breast tumor growth, but did see significantly less spontaneous mets to liver & lungs! But what about in humans?

Pleased to share our latest publication in @BCRJournal @SpringerNature ! https://t.co/3ZAXdV0MwH In 2021 we discovered that CIRBP plays an important role in the invasive growth of brain mets; we wondered if it also plays a role in metastasis more broadly 🤔

Study that went under the radar at ASCO. WBRT with hippocampal sparing and memantine versus SRS for 5-20 brain metastases. Same Overall survival, Lower Symptom Burden and Life Interference with SRS, Better KPS with SRS. New standard of care! Congrats Dr. Aizer on this amazing

Check out this awesome new study by the spatial biologists @McGillGCI led by @LysDesharnais @sorin_mark and PI @loganawalsh! Few studies provide such detail contrasting the spatial TME of LUSC and LUAD: the two dominant NSCLC histologies!

Congrats to @KAhmedMD & team on this important brain mets screening study! The cumulative incidence of brain mets among pts with HR+/HER2-ve mbc whose dz progressed on 1st line ET was quite high (23% @ 6 mo) & comparable to that of pts with HER2+ (24%) and triple neg mbc (25%).

Huge thanks to our co-authors from near and far, those on here include ➡️ @EmmaJRousselle @ANowakowski11 @annalazaratos @NicolaNormanno @ArielleElkrief @MLadanyi @DrDrAprilRose @LDI_ILD @McGillGCI

Our data suggests that Class 2 MAP2K1 mt tumors are in a sweet spot to derive benefit from MEK inhibitors, perhaps due to less reliance on upstream mts while also retaining sensitivity to approved MEK inhibitors. We hope that this data can inform Molecular TBs and future trials!

To understand whether this paradigm holds true in the real world, we assembled a dream team of @McGillMed students & residents to conduct a systematic review and meta-analysis of patients with MAP2K1 mutations treated with MAPK-targeted therapy.

In vitro studies have shown that like BRAF, MAP2K1 mts can be divided into 3 classes: Class 1 mts co-occur with upstream MAPK mts and depend on them heavilly, Class 2 mts less so, and Class 3 mts are totally independent of upstream RAF. @EmmaJRousselle made this 🔥fig to explain

With @DrDrAprilRose we've published before on the biological/clinical implications of different classes of BRAF mutations. Here we went one protein down the MAPK pathway and looked at clinical activity of MAP2K1 (MEK1) mutations, which are rare but do pop up on NGS reports!

We are excited to share our latest publication "Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers", out today in @JCOPO_ASCO ! https://t.co/zoDmQRHcZ0

Machine learning prediction of brain metastasis invasion pattern on brain magnetic resonance imaging scans Out on NeuroOncology Advances https://t.co/0fi4NajsJ0 Brain metastasis invasion pattern (BMIP) is a valuable biomarker linked to survival outcomes and therapeutic

Check out our latest article in @CurrentOncology on real-world data for HER2+ and HER2-low BC patients receiving TDXd and its effectiveness in those with brain and leptomeningeal metastases.

We're excited about the growing indications for TDXd, particularly for CNS mets. Check out our latest in which we describe the literature, future directions, and show Her2 IHC data from lung cancer brain met pts at @TheNeuro_MNI @McGillGCI @annalazaratos https://t.co/jLT7c8kYjb

Amazing summary of LMD-

📢Very excited to share this paper with you! The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy published @Nature . Congratulations to Laura, @ColindaScheele and all the authors for this amazing story. https://t.co/UvdwYsJMK8